You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / CE

Cancer and the World Trade Center Health Program

  • Authors: Elizabeth M. Ward, PhD; Michael A. Crane, MD, MPH; Mark R. Farfel, ScD; David J. Prezant, MD
  • CME / CE Released: 4/15/2016
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 4/15/2017
Start Activity


Target Audience and Goal Statement

This activity is intended for primary care physicians, nurses, hematology/oncology specialists, and public health and preventive medicine specialists.

The goal of this activity is to educate clinicians about the association between cancer and exposure to 9/11 terrorist sites as well as health services the World Trade Center Health Program (WTCHP) offers survivors and responders at risk of exposure or undergoing treatment for cancer.

Upon completion of this activity, participants will be able to:

  1. Explain why the WTCHP added cancer to the List of WTC-Related Health Conditions under the James Zadroga 9/11 Health and Compensation Act of 2010 (Zadroga Act)
  2. Recognize what cancers and screenings are covered by the WTCHP
  3. Identify the process for determining the WTC-relatedness of a disease in a patient with cancer suspected to be due to WTC exposure


Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Moderator

  • Elizabeth M. Ward, PhD

    Senior Vice President, Intramural Research, American Cancer Society, Atlanta, Georgia

    Disclosures

    Disclosure: Elizabeth M. Ward, PhD, has disclosed no relevant financial relationships.

    Dr Ward does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Ward does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Panelists

  • Michael A. Crane, MD, MPH

    Associate Professor, Department of Preventive Medicine, Icahn School of Medicine at Mount Sinai, New York, New York

    Disclosures

    Disclosure: Michael A. Crane, MD, MPH, has disclosed no relevant financial relationships.

    Dr Crane does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Crane does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

  • Mark R. Farfel, ScD

    Director, WTC Health Registry, NYC Department of Health & Mental Hygiene, New York, New York

    Disclosures

    Disclosure: Mark R. Farfel, ScD, has disclosed no relevant financial relationships.

    Dr Farfel does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Farfel does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

  • David J. Prezant, MD

    Professor of Medicine, Albert Einstein College of Medicine, Bronx, New York

    Disclosures

    Disclosure: David J. Prezant, MD, has disclosed no relevant financial relationships.

    Dr Prezant does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Prezant does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editor

  • Stacey J.P. Ullman, MHS

    Scientific Director, Medscape, LLC

    Disclosures

    Disclosure: Stacey J.P. Ullman, MHS, has disclosed no relevant financial relationships.

CME Reviewer/Nurse Planner

  • Amy Bernard, MS, BSN, RN-BC

    Lead Nurse Planner, Medscape, LLC

    Disclosures

    Disclosure: Amy Bernard, MS, BSN, RN-BC, has disclosed no relevant financial relationships.


Accreditation Statements

    For Physicians

  • Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Medscape, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Medscape, LLC staff have disclosed that they have no relevant financial relationships.

    Contact This Provider

    For Nurses

  • Medscape, LLC is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

    Awarded 0.5 contact hour(s) of continuing nursing education for RNs and APNs; none of these credits is in the area of pharmacology.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / CE

Cancer and the World Trade Center Health Program

Authors: Elizabeth M. Ward, PhD; Michael A. Crane, MD, MPH; Mark R. Farfel, ScD; David J. Prezant, MDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CME / CE Released: 4/15/2016

Valid for credit through: 4/15/2017

processing....

  • Print